IMGN News and Press, ImmunoGen Inc. From 03/01/23

ImmunoGen press release ( NASDAQ: IMGN ): Q4 GAAP EPS of -$0.23 beats by $0.07 . Revenue of $41.2M (+47.1% Y/Y) beats by $24.02M . ImmunoGen had $275.1 million in cash and cash equivalents as of December 31, 2022, compared with $478.8 million as of December 31, 2021. ...

Launched ELAHERE™ (mirvetuximab soravtansine-gynx), the First and Only ADC Approved for Platinum-Resistant Ovarian Cancer in the US; ELAHERE Monotherapy and in Combination with Bevacizumab Included in NCCN Guidelines and Compendium Top-Line Results from Confirmatory MIRASOL Trial A...

ImmunoGen to Receive a $15 Million Upfront Payment; Eligible to Receive Up to $337 Million in Potential Option Fees and Milestone Payments Plus Tiered Royalties on a Per Target Basis ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs), ...

ImmunoGen ( NASDAQ: IMGN ) is scheduled to announce Q4 earnings results on Wednesday, March 1st, before market open. The consensus EPS Estimate is -$0.30 (-76.5% Y/Y) and the consensus Revenue Estimate is $17.18M (-38.6% Y/Y). Over the last 1 year, IMGN has beaten EPS estima...

Gainers: Progyny ( PGNY ) +14% . SI-BONE ( SIBN ) +12% . AAON ( AAON ) +8% . Zoom Video Communications. ( ZM ) +6% . Revolution Medicines ( RVMD ) +5% . Losers: TPI Composites ( TPIC ) -17% . Clarus Corporation ( CLAR...

ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Wednesday, March 1, 2023 to discuss its 2022 operating results. Management will also pro...

Summary IMGN received its first approval after 40 long years. However, ocular toxicity and confusing PFS are some of the problems here. Cash is also a major problem. After spending 40 years in the lab, ImmunoGen ( IMGN ) delivered its first fully owned approved product las...

Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. The All Cap Growth Strategy follows a focused, high...

Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. The Multi Cap Growth Strategy takes a concentrated,...

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Michael Vasconcelles, MD, has been appointed Executive Vice President, Research, Development, and Medical Affairs. "Following the recent appro...